Tango Therapeutics reported on October 23 that its PRMT5 inhibitor vopimetostat, combined with Revolution Medicines’ RAS(ON) inhibitor daraxonrasib (sold as Rasonque), produced an objective response rate of 82 percent in patients with MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma who had already received two or three prior lines of therapy. The figure covers 22 efficacy-evaluable patients in the ongoing Phase 1/2 study, at a data cutoff of August 20, 2026. Median progression-free survival had not been reached, and the 9-month progression-free survival rate was 88 percent. The results were presented at the European Society for Medical Oncology Congress in Madrid.
The combination was generally well tolerated in the 30 pancreatic and lung cancer patients treated at the first dose level, and combinations with daraxonrasib or with the related RAS(ON) inhibitor zoldonrasib are both being studied. Tango said it expects to start a registrational Phase 3 study of vopimetostat plus daraxonrasib in front-line MTAP-deleted pancreatic cancer in the first half of 2027.
The caveats belong in the same paragraph as the headline. Twenty-two patients, selected for two biomarkers, in a single-arm study, is a signal and not a result: response rates in small early cohorts routinely fall as enrollment widens, and there is no control arm against which to judge the 88 percent figure. What the data do establish is that a chemotherapy-free targeted combination can shrink tumors in a disease where shrinkage is rare, which is why STAT’s account from Madrid framed the readout as support for combining targeted drugs rather than sequencing them. The Phase 3 design, and whether regulators accept the biomarker-defined population, is the next test.